Manufacturing Expansion And Peptide Expertise Will Unlock Future Opportunities

Shared on23 Apr 25
Fair value Increased 0.55%

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 3.71%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Increased 1.39%

AnalystConsensusTarget has increased profit margin from 22.3% to 25.0% and decreased shares outstanding growth rate from 0.0% to -0.0%.